Latham & Watkins Advises on Cambridge Epigenetix US$88 Million Series D Round

London emerging companies team represents lead investor in financing to advance best-in-class DNA sequencing technology platform.

November 15, 2021

Latham & Watkins advised the lead investor in Cambridge Epigenetix’s, a life sciences tools and technology company revolutionizing genome sequencing, US$88 million Series D financing, bringing its total funds raised to date to US$146 million.

Proceeds from the financing will be used to commercialize Cambridge Epigenetix’s proprietary genetic and epigenetic sequencing technology, which easily integrates into existing sequencing platforms to enable more information to be read from DNA.

The Latham team was led by London corporate partner Mike Turner, with associate Samantha Si.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.